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Abstract 
Introduction 
Respiratory syncytial virus is a very common disorder seen in 
the pediatric population. RSV may lead to severe infections 
requiring admission to a pediatric intensive care unit, 
especially in children considered to be high-risk. Palivizumab 
is a humanized monoclonal antibody that was approved in the 
United States by the FDA in 1998 to prevent RSV infections. 
The purpose of this study is to determine if the incidence of 
recurrent wheezing can be decreased by preventing RSV 
infections with palivizumab.  
Research Question 
Literature Review 




• Palivizumab can decrease recurrent wheezing throughout 
childhood 
• After correcting for variables such as daycare attendance, 
smoking in the home, furred pets in the home, number of 
people living in the home, etc., in patient groups, 
palivizumab groups were viewed to have a significant 
decrease in recurrent wheezing 
• Reduction in recurrent wheeze remained statistically 
significant up to the age of thirteen 
• Palivizumab administration can decrease clinic visits and 
hospital admissions during childhood and can improve 
quality of life  
Children who have been infected with Respiratory Syncytial 
Virus have a higher incidence of wheeze-associated clinic 
visits and hospitalizations compared to children without 
previous RSV exposure. The purpose of this study is to 
determine if palivizumab, an immunoglobulin injection used 
to prevent RSV infections, can decrease the incidence of 
recurrent wheezing in children. The review of literature will 
follow male and female children from infancy to age 13 who 
were treated with palivizumab and compare these children to 
patients with similar demographics that were not treated with 
palivizumab to determine if there is any difference in 
incidence of wheezing. The anticipated results are that 
patients treated with palivizumab will have a decreased 
incidence of recurrent wheeze. The findings may indicate that 
prevention of RSV with palivizumab will improve long-term 
health in children. 
• In patients treated with palivizumab, is there a statistical 
difference in recurrent wheeze when compared to children 
not given palivizumab? 
• Are there long-term or even lifelong benefits to preventing 
RSV with palivizumab? 
 
• RSV is the single most common cause of bronchiolitis 
• 30-40% of patients hospitalized with an RSV infection will 
wheeze later in childhood, and RSV infection in infancy 
may be on important precursor to asthma (Hay et al., 2012) 
• RSV bronchiolitis may interfere with normal lung 
development or immune maturation and subsequently cause 
recurrent episodes of wheezing (Blanken et al., 2013) 
• In a non-randomized, observational, prospective study 
conducted by Yoshihara et al. (2013) recurrent wheeze was 
reported in 18.9% of the untreated group and only 6.4% of 
the palivizumab treated group (RR, 0.34 [95% CI, 0.19-
0.60} P <0.001) 
• When comparing a palivizumab treated group to a control 
group Simoes et al. (2007) determined the palivizumab 
treated group had a longer time to onset of recurrent wheeze 
(HR=0.46, 95% CI = 0.29 to 0.74) and also a decrease in 
physician diagnosed recurrent wheeze (HR = 0.36, 95% CI 
= 0.25 to 0.83) 
• In a study conducted by Blanken et al. in 2013, there was a 
significant difference in recurrent wheeze in the treated 
group (11.2%) versus the placebo group (20.9%) (See Table 
1) 
• Stein et al. (1999) determined through a longitudinal report 
that the risk of infrequent and frequent wheezing decreased 
enough to become non-significant by the age of thirteen 
• Sigurs (2002) conducted a cohort study which determined 
that at age 7.5 years 23% of patients with RSV were 
diagnosed with asthma, whereas only 2% of the control 




• Palivizumab has limited FDA approval in the U.S. and is 
limited to high-risk infants only 
• Premature infants <35wga or infants with chronic lung 
disease of prematurity should be offered palivizumab 
• RSV prophylaxis with Synagis, palivizumab, is expensive 
and prior authorization for the antibody should be 
investigated prior to administration 
• I would like to express heartfelt appreciation to Dr. Vikki 





Statement of the Problem 
Currently only high-risk patients are receiving palivizumab due 
to the high cost associated with the injections. It is unknown if 
administration of palivizumab would be beneficial for patients 
that are not considered to be high-risk. Studies are needed to 
determine if palivizumab administration can prevent recurrent 
wheezing and the healthcare costs associated with wheeze 
related clinic visits and hospital admissions. 
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Symptoms RSV Group (n=47) Control Group (n=93) P-Value RR 95% CI
Asthma
     Cumulative 14/47 (30%) 3/93 (3%) <0.0001 9.23 2.79-30.55
     Current 11/47 (23%) 2/92 (2%) <0.001 10.88 2.51-47.11
     Current Atopic 7/47 (9%) 1/93 (1%) 0.002 13.85 1.76-109.30
Recurrent Wheezing
     Cumulative 13/47 (28%) 10/93 (11%) 0.015 2.57 1.22-5.42
     Current 6/47 (13%) 0/93 (0%) <0.001 Not Calculable
Any Wheezing
     Cumulative 32/47 (68%) 32/93 (34%) <0.001 1.98 1.40-2.79
     Current 18/47 (38%) 2/93 (2%) <0.0001 17.81 4.31-73.54
Table 2. Number (percentage) of Children with Bronchial Obstructive Symptoms in the Respiratory Syncytial Virus Group and the 
Control Group at age 7.5
"Current symptoms" means disease during the preceding year; "Current, atopic asthma" means asthma with allergic sensitisation. 
(Sigurs et al., 2002).
